Predictive Factors of Pseudoprogression in Vestibular Schwannoma Treated with Fractionated Stereotactic Radiotherapy

被引:0
|
作者
Lo, A. W. S. [1 ]
Nyaw, S. F. [2 ]
Mui, W. H. [2 ]
Huang, J. J. [2 ]
Kam, K. M. [3 ]
Wong, C. S. [2 ]
机构
[1] Prince Wales Hosp, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China
[2] Tuen Mun Hosp, Dept Clin Oncol, Tuen Mun, Hong Kong, Peoples R China
[3] Hong Kong Sanat & Hosp, Comprehens Oncol Ctr, Happy Valley, Hong Kong, Peoples R China
来源
HONG KONG JOURNAL OF RADIOLOGY | 2019年 / 22卷 / 03期
关键词
Neuroma; acoustic; Radiotherapy; Risk factors; ACOUSTIC NEUROMAS; RADIOSURGERY; RADIATION; MANAGEMENT; EXPANSION; SURGERY;
D O I
10.12809/hkjr1916934
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective: Fractionated stereotactic radiotherapy (FSRT) is a well-established treatment for vestibular schwannoma (VS). Tumour pseudoprogression may lead to worsening symptoms leading to the necessity of urgent salvage surgery. This study aimed to assess the predictive factors of pseudoprogression and treatment related toxicities in VS treated with FSRT. Methods: This retrospective cohort study included all patients with VS treated with FSRT between 1999 and 2015. Risk factors assessed included sex, age, previous surgical resection, tumour diameter, gross tumour volume, planning target volume, overall treatment time, equivalent dose in 2-Gy fractions, and the presence of brainstem or cerebellar compression prior to radiotherapy. Fisher's exact test and two-sample t test were used for statistical analysis. Results: Eighteen patients were included. The median follow-up time was 80.3 months. The overall disease control rate after FSRT was 94.4%. Of the 18 patients, one (5.6%) developed local tumour progression, seven (38.9%) underwent tumour pseudoprogression; and 10 (55.6%) had stable disease. Median time to tumour pseudoprogression was 8.63 months (range, 4.5-13.1 months). Tumours with pseudoprogression and those with at least stable disease had a mean diameter of 2.7 cm and 2.1 cm, respectively (p = 0.18). The mean treatment planning target volume in the pseudoprogression group was larger than that in the non-progression group with volume measured (22.2 cc vs. 10.0 cc; p = 0.04). Patients with brainstem or cerebellar compression observed on magnetic resonance imaging before radiotherapy were associated with a higher risk of pseudoprogression (p = 0.0498). The overall salvage surgery rate was 17.7%. Conclusion: Upfront surgery may be more desirable than FSRT for those surgically fit patients with considerable treatment volume and evidence of mass effect. Large prospective studies are needed to confirm our findings and to identify further predictive factors for pseudoprogression.
引用
收藏
页码:152 / 159
页数:8
相关论文
共 50 条
  • [21] Outcome of Vestibular Schwannoma Treated with Fractionated Radiotherapy from a Single UK Centre
    Burton, K. E.
    Prevost, T.
    Gahir, D.
    Mukesh, M.
    Harris, F.
    Jena, R.
    Burnet, N. G.
    Jefferies, S. J.
    CLINICAL ONCOLOGY, 2011, 23 (03) : S31 - S31
  • [22] Fractionated Stereotactic Radiotherapy vs. Stereotactic Radiosurgery for Vestibular Schwannoma: Local Control, Hearing Preservation, and Toxicities
    Shelukar, S.
    Poiset, S. J.
    Cappelli, L.
    Farrell, C.
    Evans, J.
    Andrews, D. W.
    Shi, W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E149 - E150
  • [23] Impact of Cochlear Dose on Hearing Preservation following Stereotactic Radiosurgery and Fractionated Stereotactic Radiotherapy for the Treatment of Vestibular Schwannoma
    Chung, Lawrance K.
    Ung, Nolan
    Sheppard, John P.
    Thien Nguyen
    Lagman, Carlito
    Choy, Winward
    Tenn, Stephen
    Pouratian, Nader
    Lee, Percy
    Kaprealian, Tania
    Selch, Michael
    De Salles, Antonio
    Gopen, Quinton
    Yang, Isaac
    JOURNAL OF NEUROLOGICAL SURGERY PART B-SKULL BASE, 2018, 79 (04) : 335 - 342
  • [24] Fractionated stereotactic radiotherapy for vestibular schwannoma: single institutional experience at the Princess Margaret Hospital, Canada
    Koh, E.
    Millar, B.-A.
    Menard, C.
    Michaels, H.
    Heydarian, M.
    Ladak, S.
    Mckinnon, S.
    Laperriere, N.
    EJC SUPPLEMENTS, 2005, 3 (02): : 136 - 136
  • [25] Comparison of fractionated stereotactic radiotherapy with proton radiosurgery for vestibular schwannoma: A risk-stratified analysis
    Chan, A. W.
    Barker, F. G.
    Lopes, V. V.
    Martuza, R.
    Loeffler, J. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (03): : S198 - S199
  • [26] Comparison between observation policy and fractionated stereotactic radiotherapy (SRT) as an initial management for vestibular schwannoma
    Shirato, H
    Sakamoto, T
    Sawamura, Y
    Kagei, K
    Isu, T
    Kato, T
    Fukuda, S
    Suzuki, K
    Soma, S
    Inuyama, Y
    Miyasaka, K
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 44 (03): : 545 - 550
  • [28] Stereotactic fractionated radiotherapy (SFR) and LINAC-radiosurgery (RS) in the treatment of vestibular schwannoma (VS)
    Ladar, C.
    Mueller, A.
    Fauser, C.
    Jacob, V
    Nieder, C.
    Molls, M.
    Grosu, A. L.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2006, 182 : 23 - 24
  • [29] Conventionally Fractionated Stereotactic Radiotherapy for Vestibular Schwannoma: A Single Institutional Long-term Outcomes
    Aoyama, H.
    Takeichi, N.
    Onodera, S.
    Taguchi, H.
    Sawamura, Y.
    Shirato, H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S8 - S9
  • [30] Vestibular schwannoma: Results of hypofractionated stereotactic radiotherapy
    Pierre-Marie, P.
    Tringali, S.
    Beldjoudi, G.
    Pommier, P.
    Tanguy, R.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S681 - S682